Phase 3
N=52
Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.
Paroxysmal Nocturnal Hemoglobinuria
Bottom Line
View on ClinicalTrials.gov: NCT05630001 ↗Enrolled (actual)
52
Serious AEs
3.9%
Results posted
Dec 2025
Primary outcome: Primary: Change in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Non-inferiority — 2.01 g/dL — p=<0.0001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Iptacopan (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Novartis Pharmaceuticals
- Primary completion
- Oct 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Non-inferiority |
2.01 | <0.0001 sig |
| SECONDARY Change in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Superiority |
2.01 | <0.0001 sig |
| SECONDARY Proportion of Hematological Responders to Iptacopan Treatment |
92.7 | — |
| SECONDARY Proportion of Participants Who Remain Free From Transfusions |
100.0 | — |
| SECONDARY Change From Baseline in Absolute Reticulocytes Count (ARC) Levels |
-89.19 | — |
| SECONDARY Percentage Change From Baseline in Lactate Dehydrogenase (LDH) Levels |
-1.30 | — |
| SECONDARY Change From Baseline in Treatment Satisfaction Score Using TSQM-9 Questionnaire |
15.08; 12.54; 20.34; 23.86; 14.26; 18.53 | — |
| SECONDARY Change From Baseline in Fatigue Score Using FACIT-F Questionnaire |
4.88; 4.29 | — |
| SECONDARY Percentage of Patients Who Had Breakthrough Hemolysis (BTH) Event |
0.00 | — |
| SECONDARY Percentage of Patients Who Had Major Adverse Vascular Events (MAVEs) |
0.00 | — |
Summary
The purpose of the study was to find out if iptacopan is effective and safe in adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who switched from their current standard of care treatment (eculizumab or ravulizumab) to study treatment, iptacopan/LNP023.
Eligibility Criteria
Inclusion Criteria
- Signed informed consent must be obtained prior to participation in the study.
- Male and female participants ≥ 18 years of age, at the time of ICF signatures and with a diagnosis of PNH confirmed by treating physician.
- Stable regimen (dose and intervals) of anti-C5 antibody treatment (either eculizumab or ravulizumab) for at least 6 months prior to screening
- Mean hemoglobin level ≥10 g/dL
- Vaccination against Neisseria meningitidis and S. pneumoniae infection are required prior to the start of iptacopan treatment.
- If not received previously, vaccination against Haemophilus influenzae infections is recommended, if available and according to local regulations.
- Ability to communicate well with the investigator, to understand and comply with the requirements of the study
- Other protocol -defined inclusion criteria may apply at the end.
Exclusion Criteria
- Participation in any other investigational drug trial or use of other investigational drugs at the time of enrollment
- Patients requiring red blood cell transfusion in the 6 months prior to screening or during screening
- History of stem cell transplantation or any solid organ transplantation
- Active systemic bacterial, viral (incl. COVID-19) or fungal infection within 14 days prior to study drug administration
- Presence of fever ≥ 38.0 °C (100.4 °F) within 7 days prior to study drug administration
- Human immunodeficiency virus (HIV) infection (known history of HIV or test positive for HIV antibody at Screening)
- A history of recurrent invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus
- Unstable medical condition including, but not limited to, myocardial ischemia, active gastrointestinal bleeding, coexisting chronic anemia unrelated to PNH, or unstable thrombotic event not amenable to active treatment as judged by the investigator at Screening.
- History of cancer of any part of the body within the past 5 years,
- Ongoing drug or alcohol abuse that could interfere with patient's participation in the trial.
- Any medical condition deemed likely to interfere with the patient's participation in the study
- Female patients who are pregnant or breastfeeding, or intending to conceive during the course of the study
Data sourced from ClinicalTrials.gov (NCT05630001). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.